Q1 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full year guidance Core Net Financial Result Expenses expected to decrease by around 0.1bn vs. 2022 (revised from broadly in line vs. 2022) Core Tax Rate Expected to be broadly in line vs. 2022 42 Investor Relations | Q1 2023 Results References Abbreviations FINANCIAL PROFILE NOVARTIS | Reimagining Medicine

View entire presentation